Treatment of Mycobacterium fortuitum pulmonary infection with “transfer factor” (TF): New methodology for evaluating TF potency and predicting clinical response

Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis

“…Thus, the immunotherapeutic effect is not species specific, although murine TF was more efficient permitting a 95% survival with a significant decrease in lung bacillary loads and tissue damage after six months of treatment. These results using an experimental model of pulmonary tuberculosis, are in agreement with several clinical studies that have reported dramatic benefits in patients treated with TF suffering cutaneous tuberculosis (lupus vulgaris) [4], pulmonary tuberculosis refractory to all antibiotics [26], tuberculous osteomyelitis [27], and infections by Mycobacterium fortuitum or Mycobacterium xenopi [8,28]. Our results extend these clinical observations, showing that TF treatment induced a significant production of IFN γ , IL‐2, and iNOS concomitantly with a significant decrease in IL‐4 expression.…”

CpG and transfer factor assembled on nanoparticles reduce tumor burden in mice glioma model

“…leishmaniasis; toxoplasmosis), immuno-deciencies (chronic granulomatosis) and even cancers. 11,[13][14][15] For example, in one clinical study, TF from lymphocytes of blank donors was employed to treat 356 patients with non-small cell lung cancer (NSCLC); the patients that received TF showed a remarkably improved survival rate, indicating that the administration of TF directly improved lung cancer survival rate. 16 In another clinical trial, 5 patients at the advanced stage of breast cancer were treated with TF donated from healthy subjects for 21 to 310 days.…”

Transfer factor and other T cell products

“…After two months, he was given DLE from a donor positive to PPD-F but negative to PPD-S. Six months later his clinical condition as measured by objective laboratory tests had improved; by 15 months of treatment he Was free of M.fortuitum and his lung had markedly improved as judged by lung roentgenogram and tissue biopsy [67]. For four months he was given four drugs commonly used against Mycobac~erium tuberculosis without benefit and then amikacim.…”

“…All DLE preparations should be evaluated for specific reactivity to antigens of the specific organism, if known, and for TF potency [66,67], using target ceils from normal nonimmune donors and specifically from the potential recipient of the DLE. All DLE preparations should be evaluated for specific reactivity to antigens of the specific organism, if known, and for TF potency [66,67], using target ceils from normal nonimmune donors and specifically from the potential recipient of the DLE.…”

“…About 15-18~ of those DLE preparations which induce specific CMI in vitro when normal target ceils are used may inhibit or suppress the CMI responses of the potential recipient. Treatment should be divided into three stages: (a) reduction of the antigen load by conventional and adequate chemotherapy and correction of any dietary deficiencies; (b) immunotherapy with DLE, injected repeatedly and in quantities sufficient to convert the patient to responsiveness to the etiologic agent as demonstrated in vitro; (c) immunoprophylaxis with DLE shouldbe given at regular intervals (no longer than 6 months after the organisms are eradicated since immunologic normalization never lasts longer than this) to maintain the patient's CMI as monitored with suitable in vitro tests for antigen-specific responsiveness [67]. 4.…”